clinical trial · NCT00508157
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase4·terminated·n = 125
Metabolic SyndromeSchizophreniaAripiprazoleContinued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
brief summary
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole for 16 weeks, with flexible dosing within a range of 10 to 30 mg once daily (QD); or ii) continue for 16 weeks on the same atypical antipsychotic treatment prior to the study enrollment.
started
Nov 1, 2007
primary completion
Mar 1, 2009
completion
Mar 1, 2009
last updated
Nov 12, 2026
official title
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol